HK1106794A1 - Anticancer agent containing dendritic cell having rna virus transferred thereinto - Google Patents

Anticancer agent containing dendritic cell having rna virus transferred thereinto

Info

Publication number
HK1106794A1
HK1106794A1 HK08100566.6A HK08100566A HK1106794A1 HK 1106794 A1 HK1106794 A1 HK 1106794A1 HK 08100566 A HK08100566 A HK 08100566A HK 1106794 A1 HK1106794 A1 HK 1106794A1
Authority
HK
Hong Kong
Prior art keywords
agent containing
dendritic cell
anticancer agent
rna virus
containing dendritic
Prior art date
Application number
HK08100566.6A
Other languages
English (en)
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2004/016089 external-priority patent/WO2005042737A1/ja
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Publication of HK1106794A1 publication Critical patent/HK1106794A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464408—Platelet-derived growth factor receptors [PDGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18832—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18871—Demonstrated in vivo effect
HK08100566.6A 2004-06-24 2008-01-16 Anticancer agent containing dendritic cell having rna virus transferred thereinto HK1106794A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004187028 2004-06-24
PCT/JP2004/016089 WO2005042737A1 (ja) 2003-11-04 2004-10-29 遺伝子導入された樹状細胞の製造方法
PCT/JP2005/008175 WO2006001122A1 (ja) 2004-06-24 2005-04-28 Rnaウイルスが導入された樹状細胞を含む抗癌剤

Publications (1)

Publication Number Publication Date
HK1106794A1 true HK1106794A1 (en) 2008-03-20

Family

ID=37866022

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100566.6A HK1106794A1 (en) 2004-06-24 2008-01-16 Anticancer agent containing dendritic cell having rna virus transferred thereinto

Country Status (9)

Country Link
US (2) US20080031855A1 (zh)
EP (2) EP1775343A4 (zh)
JP (3) JPWO2006001120A1 (zh)
KR (2) KR20070028573A (zh)
CN (2) CN101006171A (zh)
AU (2) AU2005257105A1 (zh)
CA (2) CA2571844A1 (zh)
HK (1) HK1106794A1 (zh)
WO (2) WO2006001122A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236378C (en) * 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
KR20070094989A (ko) * 2000-03-30 2007-09-27 가부시키가이샤 디나벡크 겐큐쇼 센다이바이러스 벡터를 사용한 ａｉｄｓ 바이러스 백신
JPWO2004038029A1 (ja) * 2002-10-24 2006-02-23 株式会社ディナベック研究所 Ｔ細胞に遺伝子を導入する方法
JPWO2005042737A1 (ja) * 2003-11-04 2007-05-10 株式会社ディナベック研究所 遺伝子導入された樹状細胞の製造方法
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
KR101279677B1 (ko) * 2004-01-22 2013-06-27 가부시키가이샤 디나벡크 겐큐쇼 사이토메갈로바이러스 인핸서 및 닭 β­액틴 프로모터를 포함하는 하이브리드 프로모터를 이용한 마이너스 가닥 ＲＮＡ 바이러스 벡터의 제조방법
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
WO2006001122A1 (ja) * 2004-06-24 2006-01-05 Dnavec Research Inc. Rnaウイルスが導入された樹状細胞を含む抗癌剤
EP1916298B1 (en) * 2005-06-14 2011-12-28 Dnavec Corporation Methods for producing monoclonal antibodies
CA2636600A1 (en) * 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
WO2007088882A1 (ja) * 2006-01-31 2007-08-09 Ishihara Sangyo Kaisha, Ltd. エンベロープウイルスの構成成分に親和性を有するポリペプチドと細胞内物質導入への使用
EP2377925A1 (en) 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
JPWO2008065752A1 (ja) * 2006-11-30 2010-03-04 国立大学法人北海道大学 ｄｉＲＮＡを有効成分とする免疫治療用薬剤
KR101647843B1 (ko) 2007-03-12 2016-08-11 온콜리틱스 바이오테크 인코포레이티드 변형된 서열을 갖는 레오바이러스
WO2008136438A1 (ja) * 2007-04-27 2008-11-13 Kyushu University, National University Corporation 遺伝子治療用ウイルスベクター
US8283163B2 (en) * 2007-05-17 2012-10-09 Dnavec Corporation Method for production of dendritic cell
US8719420B2 (en) * 2008-05-13 2014-05-06 At&T Mobility Ii Llc Administration of access lists for femtocell service
WO2010032764A1 (ja) * 2008-09-16 2010-03-25 ジェノミディア株式会社 前立腺癌の治療・予防剤
WO2010055900A1 (ja) 2008-11-14 2010-05-20 ディナベック株式会社 樹状細胞の製造方法
US20100266642A1 (en) * 2009-02-20 2010-10-21 Bind Biosciences, Inc. Modified cells for targeted cell trafficking and uses thereof
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
CN102822332A (zh) * 2009-12-04 2012-12-12 干细胞及再生医学国际股份有限公司 从源于人胚胎干细胞的成血管细胞产生自然杀伤细胞和树突细胞的方法
DE102010018961B4 (de) * 2010-04-23 2012-09-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen
KR101365208B1 (ko) * 2011-12-06 2014-02-20 가톨릭대학교 산학협력단 바이러스를 이용하여 제조된 심근염 치료용 면역관용 수지상 세포 및 이의 제조 방법
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
DE202016008300U1 (de) 2015-07-02 2017-07-14 PrimeVax Immuno-Oncology, Inc. Zusammensetzungen zur Kombinationstherapie mit Denguevirus und dendritischen Zellen
MX2018003757A (es) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
JP2019522481A (ja) * 2016-06-22 2019-08-15 アイカーン スクール オブ メディシン アット マウント サイナイ 自己切断リボザイムを利用したｒｎａのウイルス送達およびそのｃｒｉｓｐｒベースの適用
CN110139671A (zh) 2016-11-16 2019-08-16 普莱瓦克斯免疫肿瘤学公司 用于治疗癌症的组合免疫疗法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE69435155D1 (de) 1993-04-30 2008-12-04 Wellstat Biologics Corp Zusuammensetzungen zur Behandlung von Krebs mittels Viren
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
EP0864645B9 (en) * 1995-10-31 2006-03-22 Dnavec Research Inc. Negative-strand rna virus vector having autonomously replicating activity
CA2236378C (en) 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
WO1998006437A2 (en) 1996-08-13 1998-02-19 Chiron Corporation Compositions and methods for polynucleotide delivery
WO1998053048A1 (en) 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
JP2000253876A (ja) 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
DK1186667T3 (da) * 1999-05-18 2007-10-22 Dnavec Research Inc Kappegendeficient virusvektor af Paramyxoviridae
US20030166252A1 (en) 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
WO2003025570A1 (en) 2001-09-18 2003-03-27 Dnavec Research Inc. Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
EP1179594B1 (en) 1999-05-18 2008-06-25 Dnavec Research Inc. Ribonucleoprotein complex in paramyxovirus
US20020123479A1 (en) * 1999-12-08 2002-09-05 Song Elizabeth S. Immunostimulation mediated by gene-modified dendritic cells
US6472208B1 (en) 1999-12-13 2002-10-29 Héma-Québec Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells
KR20070094989A (ko) 2000-03-30 2007-09-27 가부시키가이샤 디나벡크 겐큐쇼 센다이바이러스 벡터를 사용한 ａｉｄｓ 바이러스 백신
JP4791651B2 (ja) 2000-05-18 2011-10-12 株式会社ディナベック研究所 外来遺伝子導入用パラミクソウイルスベクター
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
US20050013810A1 (en) 2001-05-08 2005-01-20 Waller Edmund K Regulating immune response using dendritic cells
EP1509595A4 (en) 2001-07-05 2006-02-22 Phylogix Inc METHODS FOR ISOLATING DENDRITIC CELLS
EP1441591B1 (en) 2001-09-06 2016-06-29 NorthWest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
JPWO2003029475A1 (ja) 2001-09-28 2005-01-20 株式会社ディナベック研究所 エピトープ結合β２ｍをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用
WO2003029274A2 (en) * 2001-09-28 2003-04-10 University Of North Carolina At Chapel Hill Paramyxoviruses as gene transfer vectors to lung cells
FR2838123B1 (fr) 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
WO2003102183A1 (fr) 2002-06-03 2003-12-11 Dnavec Research Inc. Vecteurs de paramyxovirus codant pour un anticorps et son utilisation
AU2002951082A0 (en) 2002-08-30 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic cellular agents
JPWO2004038029A1 (ja) 2002-10-24 2006-02-23 株式会社ディナベック研究所 Ｔ細胞に遺伝子を導入する方法
US7785583B2 (en) 2002-12-10 2010-08-31 Argos Therapeutics, Inc. In situ maturation of dendritic cells
JPWO2005042737A1 (ja) 2003-11-04 2007-05-10 株式会社ディナベック研究所 遺伝子導入された樹状細胞の製造方法
AU2005205441A1 (en) 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
CN1934257A (zh) 2004-01-22 2007-03-21 株式会社载体研究所 病毒载体的制备方法
KR101279677B1 (ko) * 2004-01-22 2013-06-27 가부시키가이샤 디나벡크 겐큐쇼 사이토메갈로바이러스 인핸서 및 닭 β­액틴 프로모터를 포함하는 하이브리드 프로모터를 이용한 마이너스 가닥 ＲＮＡ 바이러스 벡터의 제조방법
WO2005087269A1 (ja) 2004-03-16 2005-09-22 Dnavec Research Inc. 腫瘍増殖を抑制する方法
JPWO2005097988A1 (ja) 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
WO2006001122A1 (ja) 2004-06-24 2006-01-05 Dnavec Research Inc. Rnaウイルスが導入された樹状細胞を含む抗癌剤
AU2006237903A1 (en) 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease
KR20090027693A (ko) 2006-05-31 2009-03-17 디나벡크 가부시키가이샤 알츠하이머병 치료제
US8283163B2 (en) 2007-05-17 2012-10-09 Dnavec Corporation Method for production of dendritic cell

Also Published As

Publication number Publication date
EP1775343A4 (en) 2007-11-14
JP5296983B2 (ja) 2013-09-25
KR101270839B1 (ko) 2013-06-05
EP1775342A8 (en) 2007-06-20
EP1775343A1 (en) 2007-04-18
AU2005257105A1 (en) 2006-01-05
CN101006172B (zh) 2012-09-05
KR20070028573A (ko) 2007-03-12
JPWO2006001120A1 (ja) 2008-04-17
US20080014183A1 (en) 2008-01-17
CA2571849A1 (en) 2006-01-05
EP1775343A8 (en) 2007-09-26
US8889118B2 (en) 2014-11-18
EP1775342A1 (en) 2007-04-18
WO2006001122A1 (ja) 2006-01-05
JPWO2006001122A1 (ja) 2008-04-17
WO2006001120A1 (ja) 2006-01-05
US20080031855A1 (en) 2008-02-07
CN101006172A (zh) 2007-07-25
EP1775342A4 (en) 2007-11-07
CA2571844A1 (en) 2006-01-05
CN101006171A (zh) 2007-07-25
KR20070032022A (ko) 2007-03-20
JP2013151523A (ja) 2013-08-08
AU2005257107A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
HK1106794A1 (en) Anticancer agent containing dendritic cell having rna virus transferred thereinto
HK1211179A1 (zh) 免疫刺激性寡核苷酸多聚體
IL231889A0 (en) Preparations containing a dendritic cell and methods
IL191147A0 (en) Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
ZA200803522B (en) Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1985309A4 (en) NANOPARTICLE WITH WATER-SOLUBLE NON-PEPTIDIC LOW-MOLECULAR SUBSTANCE
EP1780643A4 (en) QUARANTINE SYSTEM
EP1769066A4 (en) MODIFIED ANTIGEN PRESENTATION CELLS
ZA200602386B (en) 5-Arylpyrimidines as anticancer agents
EP1747024A4 (en) DNA VIRUS MICRORNA AND METHOD FOR THEIR INHIBITION
ZA200607117B (en) Nucleic acid complexes
EP1736501A4 (en) CONJUGATED FUNCTIONAL NUCLEIC ACID-PEG
GB0408773D0 (en) Messaging system
GB0411537D0 (en) Nanoparticles comprising rna ligands
SG122904A1 (en) Nucleic acid preparation
EP1788082A4 (en) CONSTRUCTION OF NUCLEIC ACIDS
ZA200804799B (en) Peptide-dicer substrate RNA conjugates as delivery vehicles for siRNA
AU2005270917A8 (en) Gastrin-specific interfering RNA
GB0421771D0 (en) Messaging system
GB0404708D0 (en) Boron containing nanoparticles
GB0417107D0 (en) Genes II
GB0426124D0 (en) Regulatory dendritic cells
GB0414034D0 (en) Nucleic acid preparation
GB0400627D0 (en) Stationery sign messaging
GB0508061D0 (en) RNA viruses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170428